Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon Debuts New Client Portal at Bio-IT World Expo

Published: Wednesday, April 30, 2014
Last Updated: Wednesday, April 30, 2014
Bookmark and Share
MetaboLync™ is a cloud-based solution for sharing, visualizing, and analyzing metabolomics data.

Metabolon, Inc. announced the debut and impending launch of MetaboLync, the company’s innovative product offering which allows its clients to share, visualize, and explore metabolomics study results as a client directs. The company will unveil the capabilities of this new cloud-based software solution at the 2014 BIO-IT World Expo in Boston, Massachusetts on April 30th.  Corey DeHaven, Metabolon’s VP of Information Systems, is the visionary architect of the company’s metabolomics data processing, analysis and storage systems. The company will exhibit, and Corey will provide, an introduction to the portal, including a demonstration of its capabilities, in an oral presentation within the Harnessing Data & Standards session.

“The MetaboLync client portal is our first informatics solution available to external users and further exemplifies our leadership position in metabolomics research and diagnostics. Extracting functional results from the information-rich metabolomics data stream is key to advancing our and our clients’ research. This portal will empower users to more effectively visualize and navigate thru their own results interactively,” commented Metabolon’s President and CEO, John Ryals.

Informatics solutions have played an active and critical role in building Metabolon’s leading biomarker discovery and metabolomics profiling platforms, DiscoveryHD4™ and TrueMass™.  Metabolomics experiments generate a large amount of data, including both named and unnamed metabolites, group statistical analysis, and biological pathway annotations. Data visualization and analytical tools are required to aid in understanding the data, including relationships among detected metabolites and their effects on the underlying biology. MetaboLync leverages cloud-based resources and web service application program interfaces (APIs) to enable these functions.  Equally important, this portal solution will enable Metabolon’s clients to directly access their metabolomics study results as well as final reports interpreted by our biochemists that detail the biological significance of those results.  We expect MetaboLync portal access will be available to clients for active research studies on May 15th when the company plans to migrate to a new website platform.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Quantose IR™ Measures Insulin Sensitivity Better
Results were recently published online by the Journal of Clinical Endocrinology & Metabolism.
Wednesday, April 01, 2015
Metabolon, Baylor Partner to Screen for Inborn Errors of Metabolism
The two-year, exclusive agreement will provide global Metabolomic-Assisted Pathway Screening (MAPS) services for individuals with suspected inborn errors of metabolism (IEMs).
Thursday, September 04, 2014
Metabolon, Geisinger Partner on Prediabetes Study
Metabolon will sponsor a pilot study to evaluate its Quantose IRTM test as a monitor of glycemic control in people with prediabetes.
Friday, June 27, 2014
New Study Reveals Interplay between Genetics and Metabolism in Complex Disease
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments.
Saturday, May 17, 2014
Interplay between Genetics and Metabolism in Complex Disease Revealed
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments
Friday, May 16, 2014
Metabolon Enters into Collaboration with GSK
Agreement will see Metabolon provide metabolomic profiling services to GlaxoSmithKline.
Wednesday, May 14, 2014
Microbes and Metabolites Fuel an Ambitious Aging Project
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Wednesday, March 12, 2014
Collaboration Agreement to provide Metabolomic Profiling Services
Metabolon Inc will assist Human Longevity Inc to build the world’s largest and most complete human genotype, microbiome and phenotype database.
Wednesday, March 05, 2014
Metabolon Closes $15 Million Series E Financing
Company raises $15 million through the issuance of preferred stock.
Monday, January 06, 2014
Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Metabolon and Bostwick Laboratories Announce Marketing Agreement
Under the Agreement Bostwick will market Prostarix™, a non-invasive urine test for stratifying prostate cancer risk.
Monday, November 04, 2013
Metabolon Announces Findings from Two Major Diabetes Outcomes Studies
This provides further evidence that the Quantose test identifies individuals at risk for type 2 diabetes earlier and more accurately than traditional risk factors alone.
Tuesday, June 25, 2013
Impaired Metabolism in Cystic Fibrosis Lung Epithelial Cells Revealed by Metabolic Analysis
Metabolon announces publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”.
Monday, October 25, 2010
Metabolon Awarded US Patent for Metabolic Biomarkers of Efficacy of PPAR Affecting Drugs
The USPTO awarded the patent to Metabolon on October 5, 2010.
Thursday, October 21, 2010
Metabolon Extends Biochemical Understanding of Alzheimers Disease
Publishes “Ablation of the Locus Coeruleus Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice” in the International Journal of Alzheimer Disease.
Thursday, October 14, 2010
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos